April 12, 2022
Marinomed Biotech AG signs new agreement for Carragelose with Hanmi Pharmaceutical in South Korea
Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, has announced today that the Carragelose-based nasal spray has been out-licensed for the South Korean market.